BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21576630)

  • 1. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
    Bourhis J; Blanchard P; Maillard E; Brizel DM; Movsas B; Buentzel J; Langendijk JA; Komaki R; Swan Leong S; Levendag P; Pignon JP
    J Clin Oncol; 2011 Jun; 29(18):2590-7. PubMed ID: 21576630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
    Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
    J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
    Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
    J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis.
    Mell LK; Malik R; Komaki R; Movsas B; Swann RS; Langer C; Antonadou D; Koukourakis M; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):111-8. PubMed ID: 17289291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential for use of amifostine in cervical cancer.
    Small W
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):34-7. PubMed ID: 12577241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What should the optimal timing be for amifostine administration relative to radiation and chemotherapy?
    Komaki R
    J Clin Oncol; 2005 Oct; 23(28):7232-3; author reply 7233-5. PubMed ID: 16192612
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new administration schedule for amifostine as a radioprotector in cancer therapy.
    Wagner W; Radmard A; Schönekaes KG
    Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
    Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
    Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.
    Werner-Wasik M; Langer C; Movsas B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):47-51. PubMed ID: 15726523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine.
    Mehta MP
    Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):14-6. PubMed ID: 9794996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S; Hoffmanns H
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies.
    Vogt HG; Martin T; Kolotas C; Schneider L; Strassmann G; Zamboglou N
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-101-S12-105. PubMed ID: 9331131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
    Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
    Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.
    Sarna L; Swann S; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Byhardt R; Wasserman T; Movsas B
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1378-84. PubMed ID: 18501528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
    Mehta V
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.